Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach

@article{III2015OctreoscanVF,
  title={Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach},
  author={MS Malcolm H. Squires III and N. Volkan Adsay and David M. Schuster and Maria C. Russell and Kenneth Cardona and Keith A. Delman and Joshua H. Winer and Deniz Altinel and J. Manuel Sarmiento and Bassel F El-Rayes and Natalyn Nicole Hawk and Charles A. Staley and Shishir Kumar Maithel and David A. Kooby},
  journal={Annals of Surgical Oncology},
  year={2015},
  volume={22},
  pages={2295-2301}
}
Clinicians may order Octreoscan or positron emission tomography (PET) scan for staging patients with neuroendocrine tumors (NETs). 111In-Octreoscan (Octreoscan) identifies tumors by radiolabeled targeting of somatostatin receptors, while 18F-fluorodeoxyglucose-positron emission tomography (18FDG-PET) measures differential tissue glucose transport. We assessed the sensitivity of both nuclear imaging modalities with pathologic correlation to define the best initial choice for NET staging after… CONTINUE READING